Richard W J Groen
Overview
Explore the profile of Richard W J Groen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2000
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Varela-Moreira A, van Straten D, van Leur H, Ruiter R, Deshantri A, Hennink W, et al.
Int J Pharm X
. 2020 Jun;
2:100049.
PMID: 32490374
Carfilzomib-loaded polymeric micelles (CFZ-PM) based on poly(ethylene glycol)-b-poly(N-2-benzoyloxypropyl methacrylamide) (mPEG-b-p(HPMA-Bz)) were prepared with the aim to improve the maximum tolerated dose of carfilzomib in a "humanized" bone marrow-like scaffold model....
12.
Ren Z, Ahn J, Liu H, Tsai Y, Bhanu N, Koss B, et al.
Blood
. 2019 Aug;
134(14):1176-1189.
PMID: 31383640
Dysregulation of polycomb repressive complex 2 (PRC2) promotes oncogenesis partly through its enzymatic function for inducing trimethylation of histone H3 lysine 27 (H3K27me3). However, it remains to be determined how...
13.
Holthof L, van der Horst H, van Hal-van Veen S, Ruiter R, Li F, Buijze M, et al.
Haematologica
. 2019 May;
105(2):e80-e83.
PMID: 31123033
No abstract available.
14.
Drent E, Poels R, Ruiter R, van de Donk N, Zweegman S, Yuan H, et al.
Clin Cancer Res
. 2019 Apr;
25(13):4014-4025.
PMID: 30979735
Purpose: Targeting nonspecific, tumor-associated antigens (TAA) with chimeric antigen receptors (CAR) requires specific attention to restrict possible detrimental on-target/off-tumor effects. A reduced affinity may direct CAR-engineered T (CAR-T) cells to...
15.
Deshantri A, Fens M, Ruiter R, Metselaar J, Storm G, van Bloois L, et al.
J Control Release
. 2019 Jan;
296:232-240.
PMID: 30682443
Glucocorticoids are the cornerstone in the clinic for treatment of hematological malignancies, including multiple myeloma. Nevertheless, poor pharmacokinetic properties of glucocorticoids require high and frequent dosing with the off-target adverse...
16.
Naik J, Themeli M, de Jong-Korlaar R, Ruiter R, Poddighe P, Yuan H, et al.
Haematologica
. 2018 Sep;
104(3):e100-e103.
PMID: 30190344
No abstract available.
17.
Frerichs K, Nagy N, Lindenbergh P, Bosman P, Marin Soto J, Broekmans M, et al.
Expert Rev Clin Immunol
. 2018 Feb;
14(3):197-206.
PMID: 29465271
Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients...
18.
Krejcik J, Frerichs K, Nijhof I, van Kessel B, van Velzen J, Bloem A, et al.
Clin Cancer Res
. 2017 Oct;
23(24):7498-7511.
PMID: 29025767
Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of...
19.
Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, et al.
Mol Ther
. 2017 May;
25(8):1946-1958.
PMID: 28506593
Chimeric antigen receptors (CARs) can effectively redirect cytotoxic T cells toward highly expressed surface antigens on tumor cells. The low expression of several tumor-associated antigens (TAAs) on normal tissues, however,...
20.
Carretta M, de Boer B, Jaques J, Antonelli A, Horton S, Yuan H, et al.
Exp Hematol
. 2017 May;
51:36-46.
PMID: 28456746
Recently, NOD-SCID IL2Rγ (NSG) mice were implanted with human mesenchymal stromal cells (MSCs) in the presence of ceramic scaffolds or Matrigel to mimic the human bone marrow (BM) microenvironment. This...